National Travel Health Network and Centre, London, UK; Foreign and Commonwealth Office, London, UK; Centre for Occupational and Environmental Health, School of Medicine, The University of Manchester, Manchester, UK.
Travel Med Infect Dis. 2013 Sep-Oct;11(5):266-73. doi: 10.1016/j.tmaid.2013.08.007. Epub 2013 Sep 5.
In March 2013, the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunisation (SAGE) considered a number of issues in order to update the WHO Position Paper on Yellow Fever (2003). A key conclusion of this review was that a single dose of yellow fever (YF) vaccine appears to confer life-long protection against YF disease, and that a booster dose of YF vaccine is not needed to maintain immunity. While the efficacy of YF vaccine in the majority of vaccine recipients is not in doubt, the WHO announcement is somewhat surprising as there are some limitations in the evidence base, but more importantly, this announcement is not accompanied by any imminent change in the International Health Regulations 2005. The tension between what is considered best clinical practice and the law will be difficult to reconcile for many health professionals, travellers, and the travel industry, in an area of travel medicine that is already subject to debate and confusion. This commentary reviews the recent WHO announcement, and considers the practical implications for health professionals providing YF vaccine to international travellers.
2013 年 3 月,世界卫生组织(世卫组织)免疫战略咨询专家组(SAGE)审议了若干问题,以便更新世卫组织黄热病立场文件(2003 年)。这次审查的一个重要结论是,一剂黄热病(YF)疫苗似乎可以提供终身保护,免受 YF 疾病的侵害,而且不需要加强 YF 疫苗接种来维持免疫力。虽然 YF 疫苗在大多数疫苗接种者中的功效毋庸置疑,但世卫组织的宣布有些令人惊讶,因为证据基础存在一些局限性,但更重要的是,这一宣布并没有伴随着 2005 年《国际卫生条例》的任何即将发生的变化。对于许多卫生专业人员、旅行者和旅游业来说,在旅行医学领域,最佳临床实践和法律之间的紧张关系将难以调和,而该领域已经存在争议和混乱。本评论审查了世卫组织最近的宣布,并考虑了向国际旅行者提供 YF 疫苗对卫生专业人员的实际影响。